Company
Headquarters: Cambridge, MA, United States
Founded: 2008
Employees: 390
CEO: Dr. Jacqualyn A. Fouse
$2.42 Billion
USD as of July 1, 2024
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $622.07 B |
Vertex Pharmaceuticals Incorporated | $121.36 B |
Regeneron Pharmaceuticals, Inc. | $115.11 B |
CSL Limited | $95.75 B |
Marinomed Biotech AG | $75.67 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Top 1-year algo backtest: +177.66%
$10,000 in August 2023 would now be $27,766 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Agios Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: AGIO wb_incandescent
Stock: FSX: 8AP wb_incandescent
Jackie Fouse (CEO)
Revenue: $118 Million(2019)